MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Repro Med Systems Gross Profit 2011-2026 | KRMD
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Repro Med Systems
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.6 M | 21.3 M | 16.7 M | 15.4 M | 13.8 M | 14.9 M | 14.9 M | 10.8 M | 7.57 M | 7.6 M | 6.69 M | 5.31 M | 4.94 M | 4.14 M | 3.26 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.6 M | 3.26 M | 11.5 M |
Quarterly Gross Profit Repro Med Systems
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.23 M | 6.26 M | 6.48 M | 6.05 M | - | 5.19 M | 5.48 M | 5.1 M | - | 4.34 M | 3.89 M | 4.15 M | - | 4.32 M | 3.35 M | 3.62 M | - | 3.5 M | 3.21 M | 3.23 M | - | 3.94 M | 4.91 M | 3.79 M | - | 4.38 M | 3.48 M | 3.05 M | - | 2.89 M | 2.74 M | 2.47 M | - | 2.38 M | 2.3 M | 2.1 M | 2.06 M | 2.03 M | 1.79 M | - | 2.11 M | 5.63 M | 3.52 M | - | 1.58 M | 4.74 M | 3.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.23 M | 1.58 M | 3.8 M |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
2.68 B | $ 60.08 | -0.5 % | $ 12 B |  USA |
 |
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M | USA |
 |
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | USA |
 |
iRhythm Technologies
IRTC
|
527 M | $ 115.64 | 1.3 % | $ 3.7 B | USA |
 |
ICU Medical
ICUI
|
822 M | $ 120.74 | -1.83 % | $ 2.98 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
6.64 B | $ 425.83 | -0.52 % | $ 152 B | USA |
 |
LeMaitre Vascular
LMAT
|
179 M | $ 97.36 | -2.15 % | $ 2.2 B | USA |
 |
Alcon
ALC
|
5.74 B | $ 63.82 | -0.31 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
1 B | $ 178.36 | - | $ 9.51 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
6.84 M | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.49 B | $ 23.62 | -0.96 % | $ 3.97 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
27.8 M | $ 6.08 | -5.52 % | $ 51.6 K | USA |
 |
Haemonetics Corporation
HAE
|
749 M | $ 57.3 | 0.37 % | $ 2.88 B | USA |
 |
STAAR Surgical Company
STAA
|
182 M | $ 32.72 | 2.22 % | $ 1.62 B | USA |
 |
STERIS plc
STE
|
2.4 B | $ 213.38 | -1.2 % | $ 21 B | USA |
 |
Teleflex Incorporated
TFX
|
307 M | $ 129.54 | -0.57 % | $ 5.78 B | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
239 M | $ 142.4 | 0.16 % | $ 6.9 B | USA |
 |
InfuSystem Holdings
INFU
|
80.3 M | $ 8.73 | 1.39 % | $ 180 M | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 1.89 | 2.17 % | $ 86.5 M |  Israel |
 |
Milestone Scientific
MLSS
|
6.41 M | $ 0.33 | -2.12 % | $ 27.1 M | USA |
 |
Merit Medical Systems
MMSI
|
738 M | $ 61.83 | -1.17 % | $ 3.66 B | USA |
 |
Utah Medical Products
UTMD
|
5.26 M | $ 63.27 | -0.68 % | $ 205 M | USA |
 |
West Pharmaceutical Services
WST
|
1.1 B | $ 303.19 | 1.0 % | $ 21.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 9.98 | -4.13 % | $ 1.99 B | USA |
 |
Retractable Technologies
RVP
|
47 K | $ 0.69 | - | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
19.5 M | $ 59.84 | 2.03 % | $ 197 M | USA |
 |
Predictive Oncology
POAI
|
1.02 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
62.1 M | $ 20.52 | -2.56 % | $ 980 M | USA |
 |
Stereotaxis
STXS
|
17.1 M | $ 1.88 | -3.34 % | $ 171 M | USA |
 |
Baxter International
BAX
|
3.38 B | $ 17.32 | -2.62 % | $ 8.89 B | USA |
 |
ResMed
RMD
|
2.02 B | $ 203.11 | 0.32 % | $ 29.7 B | USA |
 |
AtriCure
ATRC
|
401 M | $ 28.04 | -0.41 % | $ 1.34 B | USA |
 |
Harvard Bioscience
HBIO
|
49.9 M | $ 5.34 | -3.26 % | $ 237 M | USA |
 |
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
158 M | $ 10.92 | -1.0 % | $ 446 M | USA |
 |
Becton, Dickinson and Company
BDX
|
8.29 B | $ 142.12 | -1.63 % | $ 40.9 B | USA |
 |
Nephros
NEPH
|
11.6 M | $ 3.27 | -2.1 % | $ 34.7 M | USA |
 |
OraSure Technologies
OSUR
|
48.2 M | $ 3.12 | 5.59 % | $ 229 M | USA |
 |
Repligen Corporation
RGEN
|
151 M | $ 106.1 | 2.63 % | $ 5.97 M | USA |